Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Cuorips, Ordinary Profit Forecast for the Fiscal Year Loss Widened in Downward Revision
4894 Cuorips Inc. 【J-GAAP】
Earnings ReportCuorips Inc. <4894> [TSE Growth] announced its financial results after the market closed on February 13th (15:30). The consolidated ordinary loss for the cumulative third quarter of the fiscal year ending March 2026 (April to December) expanded to a loss of 734 million yen (compared to a loss of 608 million yen in the same period last year).
In addition, the full-year forecast for consolidated ordinary profit/loss has been revised downward from an expected loss of 883 million yen to a loss of 981 million yen (compared to a loss of 642 million yen in the previous period), indicating an expansion in the loss margin.
Based on the full-year plan announced by the company after the downward revision, our estimate of the consolidated ordinary profit/loss for the October to March period (second half) has been revised downward from an expected loss of 400 million yen to a loss of 498 million yen (compared to a loss of 178 million yen in the same period of the previous year), indicating an expansion in the loss margin.
In the most recent three-month period, from October to December (3Q), the consolidated ordinary loss expanded to a loss of 251 million yen (compared to a loss of 144 million yen in the same period last year). The operating profit/loss margin drastically worsened from -873.7% in the same period last year to -1840.0%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Dec, 2023 | 15 | -461 | -500 | -503 | -70.2 | ー | Feb 13, 2024 | J-GAAP |
| Apr - Dec, 2024 | 26 | -564 | -608 | -611 | -76.6 | ー | Feb 13, 2025 | J-GAAP |
| Apr - Dec, 2025 | 207 | -771 | -734 | -732 | -89.3 | ー | Feb 13, 2026 | J-GAAP |
| YoY | +696.2% | -36.7% | -20.7% | -19.8% | -16.6% |
Guidance Update
Second Half Update
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2025 Prev | 398 | -400 | -400 | -406 | -49.2 | 0 | Nov 13, 2025 | J-GAAP |
| Oct - Mar, 2025 New | 20 | -529 | -498 | -500 | -60.6 | 0 | Feb 13, 2026 | J-GAAP |
| Revision Rate | -95.0% | -32.3% | -24.5% | -23.2% | -23.2% |
Full Year Update
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2026 Prev | 590 | -895 | -883 | -889 | -107.8 | 0 | May 14, 2025 | J-GAAP |
| Mar, 2026 New | 212 | -1,024 | -981 | -983 | -119.2 | 0 | Feb 13, 2026 | J-GAAP |
| Revision Rate | -64.1% | -14.4% | -11.1% | -10.6% | -10.6% |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 168 | -192 | -178 | -178 | -22.3 | 0 | May 14, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | 20 | -529 | -498 | -500 | -60.6 | 0 | Feb 13, 2026 | J-GAAP |
| YoY | -88.1% | -175.5% | -179.8% | -180.9% | -172.3% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 23 | -588 | -627 | -632 | -85.9 | 0 | May 13, 2024 | J-GAAP |
| Mar, 2025 | 175 | -590 | -642 | -644 | -80.5 | 0 | May 14, 2025 | J-GAAP |
| Mar, 2026 Guidance | 212 | -1,024 | -981 | -983 | -119.2 | 0 | Feb 13, 2026 | J-GAAP |
| YoY | +21.1% | -73.6% | -52.8% | -52.6% | -48.0% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 19 | -166 | -144 | -145 | -18.2 | -873.7 | Feb 13, 2025 | J-GAAP |
| Jan - Mar, 2025 | 149 | -26 | -34 | -33 | -4.1 | -17.4 | May 14, 2025 | J-GAAP |
| Apr - Jun, 2025 | 85 | -196 | -199 | -200 | -24.7 | -230.6 | Aug 13, 2025 | J-GAAP |
| Jul - Sep, 2025 | 107 | -299 | -284 | -283 | -34.7 | -279.4 | Nov 13, 2025 | J-GAAP |
| Oct - Dec, 2025 | 15 | -276 | -251 | -249 | -30.4 | -1,840.0 | Feb 13, 2026 | J-GAAP |
| YoY | -21.1% | -66.3% | -74.3% | -71.7% | -67.2% |
Related Articles
Terminalcare Support Institute, 49% Increase in Ordinary Profit for The Current Fiscal Year
Startia Holdings, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 6%, Raises Record High Profit Forecast, Dividend Revised Upward by 10 Yen
SECURE, 2.0 times Increase in Ordinary Profit, Update Record High for Fourth Consecutive Term
Kubota Pharma, Last Fiscal Year's Net Income Loss Narrows, Current period performance is undisclosed.
eGuarantee, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 5%, Oct-Dec Ordinary Profit Increases by 3%
Nxera Pharma, Last Fiscal Year's Net Income Loss Widens, Current period performance is undisclosed.
MEEQ, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 63%, Oct-Dec Ordinary Profit Increases by 2.1 times
Thinca, The Current Fiscal Year's Net Income Turns to Loss
OPTORUN, 2.3 times Increase in Ordinary Profit for The Current Fiscal Year, Dividend Raised by 2 Yen
NOVARESE, 89% Increase in Net Income for the Last Fiscal Year, Current period performance is undisclosed.